Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

G1 THERAPEUTICS, INC.

(GTHX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/17/2021 09/20/2021 09/21/2021 09/22/2021 09/23/2021 Date
15.55(c) 15.1(c) 14.96(c) 15.07(c) 15.32(c) Last
2 645 456 1 136 568 493 236 620 590 542 962 Volume
+8.97% -2.89% -0.93% +0.74% +1.66% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 35,7 M - -
Net income 2021 -149 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,30x
Yield 2021 -
Sales 2022 60,3 M - -
Net income 2022 -165 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,21x
Yield 2022 -
Capitalization 649 M 649 M -
Capi. / Sales 2021 18,2x
Capi. / Sales 2022 10,8x
Nbr of Employees 122
Free-Float 91,0%
More Financials
Company
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It... 
More about the company
Ratings of G1 Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about G1 THERAPEUTICS, INC.
09/16G1 THERAPEUTICS : Announces new supplemental cosela (trilaciclib) sales force
AQ
09/15G1 THERAPEUTICS : Announces New Supplemental COSELA™ (Trilaciclib) Sales Force (Form ..
PU
09/15G1 THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
AQ
09/15G1 THERAPEUTICS : Announces New Supplemental COSELA™ (Trilaciclib) Sales Force
AQ
09/15G1 Therapeutics Announces New Supplemental CoselaÖ (Trilaciclib) Sales Force
CI
09/06G1 THERAPEUTICS : Announces inducement grants under nasdaq listing rule 5635(4)
AQ
09/06G1 THERAPEUTICS : To participate in two upcoming september conferences
AQ
09/03G1 THERAPEUTICS : to Participate in Two Upcoming September Conferences
AQ
09/03G1 THERAPEUTICS : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
09/01G1 THERAPEUTICS : Roth Capital Adjusts Price Target on G1 Therapeutics to $56 From $57, Ma..
MT
08/05G1 THERAPEUTICS : Granted new technology add-on payment for cosela by centers for medicare..
AQ
08/05G1 THERAPEUTICS : Wedbush Adjusts Price Target on G1 Therapeutics to $38 From $59; Outperf..
MT
08/04G1 THERAPEUTICS : Provides Second Quarter 2021 Financial Results and Operational Highlight..
PU
08/04G1 THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results ..
AQ
08/04G1 THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statement..
AQ
More news
News in other languages on G1 THERAPEUTICS, INC.
01/22BB Biotech a étoffé ses gains en 2020 et va en faire profiter ses actionnaires
More news
Analyst Recommendations on G1 THERAPEUTICS, INC.
More recommendations
Chart G1 THERAPEUTICS, INC.
Duration : Period :
G1 Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends G1 THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 15,32 $
Average target price 50,86 $
Spread / Average Target 232%
EPS Revisions
Managers and Directors
Jack Bailey President, Chief Executive Officer & Director
Jennifer K. Moses Chief Financial Officer
Garry Allen Nicholson Chairman
Rajesh K. Malik Chief Medical Officer
Terry L. Murdock Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
G1 THERAPEUTICS, INC.-14.84%649
GILEAD SCIENCES, INC.23.05%89 497
BIONTECH SE333.01%81 938
WUXI APPTEC CO., LTD.33.88%69 841
REGENERON PHARMACEUTICALS33.82%67 273
VERTEX PHARMACEUTICALS-21.68%47 805